Related references
Note: Only part of the references are listed.Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update
Elizabeth J. Phillips et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Immunogenicity of biologics in inflammatory bowel disease
Severine Vermeire et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2018)
HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease
A. Wilson et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
Siew C. Ng et al.
LANCET (2017)
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update
Y. Saito et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
Giulia Roda et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2016)
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Infliximab-Related Infusion Reactions: Systematic Review
Lev Lichtenstein et al.
JOURNAL OF CROHNS & COLITIS (2015)
Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 Update
M. A. Martin et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Remo Panaccione et al.
GASTROENTEROLOGY (2014)
HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants
Graham A. Heap et al.
NATURE GENETICS (2014)
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
Niels Vande Casteele et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective
Fabien B. Vincent et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
American Gastroenterological Association Institute Guideline on the Use of Thiopurines, Methotrexate, and Anti-TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease
Jonathan P. Terdiman et al.
GASTROENTEROLOGY (2013)
Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature
G. Cullen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Assessing Response and Loss of Response to Biological Therapies in IBD
Henit Yanai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing
M. V. Relling et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Correlation Between the Crohn's Disease Activity and Harvey-Bradshaw Indices in Assessing Crohn's Disease Severity
Severine Vermeire et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
MECHANISMS OF DISEASE Inflammatory Bowel Disease
Clara Abraham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis
James D. Lewis et al.
INFLAMMATORY BOWEL DISEASES (2008)
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial
Geert D'Haens et al.
LANCET (2008)
The HLA system: Genetics, immunology, clinical testing, and clinical implications
Sung Yoon Choo
YONSEI MEDICAL JOURNAL (2007)
Predicting the Crohn's disease activity index from the Harvey-Bradshaw index
WR Best
INFLAMMATORY BOWEL DISEASES (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Share Paper
